Alyeska Investment Group
CAMP icon

Alyeska Investment Group’s CAMP4 Therapeutics CAMP Stock Holding History

Alyeska Investment Group’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200,000
Closed -$1.23M – 630
2025
Q4 		$1.23M Hold
200,000
– – ﹤0.01% 538
2025
Q3 		$600K Hold
200,000
– – ﹤0.01% 555
2025
Q2 		$290K Hold
200,000
– – ﹤0.01% 534
2025
Q1 		$800K Hold
200,000
– – ﹤0.01% 450
2024
Q4 		$1.04M Buy
+200,000
New +$1.64M ﹤0.01% 493

Other funds holding CAMP

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alyeska Investment Group's CAMP Position: Q1 2026 in Review

Alyeska Investment Group sold out of CAMP4 Therapeutics (CAMP) in Q1 2026, closing a stake of 200,000 shares — an estimated $1.23M sold.

Alyeska Investment Group first reported a position in CAMP in Q4 2024 and held it in 5 quarters. The position peaked at $1.23M in Q4 2025. 46 funds tracked by Wall St. Rank hold CAMP as of Q1 2026.

  • Alyeska Investment Group reported no remaining CAMP4 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Alyeska Investment Group sold 200,000 CAMP4 Therapeutics shares in Q1 2026, an estimated $1.23M.
  • Alyeska Investment Group first reported a position in CAMP4 Therapeutics in Q4 2024 and held it in 5 quarters.
  • Alyeska Investment Group's CAMP4 Therapeutics position peaked at $1.23M in Q4 2025.
  • 46 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.